PTC Therapeutics | PTCT - Net Income


PTC Therapeutics reported $-2.81M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Acadia Pharmaceuticals USD 31.5M 27.86M Jun/2026
Alnylam Pharmaceuticals USD 164.49M 41.5M Jun/2026
Amgen USD 2.38B 556M Jun/2026
BioCryst Pharmaceuticals USD 78.4M 167.45M Jun/2026
Biogen USD 97.5M 222M Jun/2026
BioMarin Pharmaceutical USD 44.76M 60.76M Jun/2026
Cytokinetics USD -198.76M 7.27M Jun/2026
Daiichi Sankyo JPY 68.64B 18B Jun/2026
Enanta Pharmaceuticals USD -22.29M 93.76M Dec/2024
Gilead Sciences USD -10.5B 12.52B Jun/2026
Incyte USD 585.6M 282.27M Jun/2026
Ionis Pharmaceuticals USD -114.65M 21.65M Jun/2026
Ironwood Pharmaceuticals USD 3.19M 457K Dec/2024
Karyopharm Therapeutics USD -22.39M 79.81M Mar/2026
Novartis USD 3.26B 108M Jun/2026
Pfizer USD -248M 2.94B Jun/2026
PTC Therapeutics USD -2.81M 132.16M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Roche Holding CHF 6.87B 1.4B Jun/2026
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sarepta Therapeutics USD 330.96M 743.18M Mar/2026
TG Therapeutics USD 7.78M 12M Jun/2026
Ultragenyx Pharmaceutical USD -185M 56M Mar/2026
Vertex Pharmaceuticals USD 1.1B 68.4M Jun/2026
Xencor USD -21.73M 107.19M Jun/2026